Optimizing Glycemic Control: A Continuing Quality Improvement Program for Primary Care
Endocrinology
Curriculum:
Improving the Quality of Care in Patients with Diabetes through a Simulated QI Experience
Improving the Quality of Care in Patients with Diabetes through a Simulated QI Experience
Credits:
1 AMA PRA Category 1 Credit(s) ™
1 AMA PRA Category 1 Credit(s) ™
Launch Date:
July 10, 2018
July 10, 2018
Expiration Date:
The accreditation for this activity has expired.
The accreditation for this activity has expired.
Primary Audience:
Primary Care Clinicians
Relevant Terms:
Type 2 Diabetes; primary care; quality improvement
Carol Wysham, MD
Carol Wysham, MD
Clinical Professor of Medicine
University of Washington School of Medicine
Endocrinologist
Rockwood Center for Diabetes and Endocrinology
Spokane, WA
Bio
Dr. Carol Wysham is Clinical Professor of Medicine at the University of Washington in Spokane and is an endocrinologist at the Rockwood Center for Diabetes and Endocrinology. Dr. Wysham chaired the American Diabetes Association Professional Practice Committee from 2011- 2013, the Endocrine Society's annual scientific meeting in 2016, and the Washington State Diabetes Collaborative from 2001 - 2009. She has over 25 years of clinical research experience, including as site Principal Investigator on the ADOPT, ACCORD, LEADER, EMPA-REG, CANVAS and FLAT-SUGAR trials.Davida F. Kruger, MSN, APN-BC, BC-ADM
Davida F. Kruger, MSN, APN-BC, BC-ADM
Certified Nurse Practitioner
Henry Ford Health System, Division of Endocrinology
Diabetes and Bone Disease
Detroit, MI
Bio
Davida F. Kruger has been a certified nurse practitioner in diabetes for more then 30 years at Henry Ford Health System in Detroit, Michigan. Her role includes both clinical practice and research. She is board certified by the American Nurses Association Credentialing Center in Primary Care and by the American Association of Diabetes Educators in Advanced Diabetes Management. She is past Chair of the American Diabetes Associations Research Foundation and has served on the American Diabetes Association's Research Policy Committee. She is also a past president, health Care and Education of the American Diabetes Association. She served as editor of Diabetes Spectrum from 2005-2008. She served as the Editor In Chief of Clinical Diabetes from 2011-2016.Ms Kruger has been a principal investigator on numerous research projects and has written widely on diabetes care, authoring the book The Diabetes Travel Guide 2nd edition (2006). Her awards include the Florence Nightengale award for excellence in research, ADA's Rachmeil Levine Award for Distinguished Service, Ada's Award for Outstanding Service in Diabetes Research Funding, The ADA Wendell May's Award, The 2014 Clara Ford Award for Nursing Excellence in Research and Education and Wayne State University School of Nursing 2014 Alumna of the year.
Felice Caldarella, MD, FACE, FACP, CDE
Felice Caldarella, MD, FACE, FACP, CDE
Endocrinologist
Center for Endocrine Health
Hunterdon Medical Center
Clinton, NJ
Bio
Dr. Caldarella provided external review for this activity. He is a graduate of New York University and received his medical degree from S.U.N.Y. Upstate Medical University. He completed his residency at Brown University in Rhode Island. Dr. Caldarella went on to receive subspecialty training in Endocrinology, Diabetes and Metabolism at UMDNJ. He is board certified in Endocrinology, Diabetes and Metabolism. He is a Fellow of the American College of Endocrinology and a Fellow of the American College of Physicians. He is also a Certified Diabetes Educator. | 1. | Outline the benefits, indications, and role of continuous glucose monitoring (CGM) in optimizing glycemic control in patients with T2DM | 2. | Describe the clinical and pharmacokinetic/pharmacodynamic (PK/PD) differences between ultralong-acting and conventional basal insulins |
| 3. | Incorporate newer basal insulins to optimize diabetes therapy and achieve A1C goals |
| 1. | Outline the benefits, indications, and role of continuous glucose monitoring (CGM) in optimizing glycemic control in patients with T2DM |
| 2. | Describe the clinical and pharmacokinetic/pharmacodynamic (PK/PD) differences between ultralong-acting and conventional basal insulins |
| 3. | Incorporate newer basal insulins to optimize diabetes therapy and achieve A1C goals |
LAUNCH DATE/EXPIRATION DATE
This activity was launched on July 10, 2018 and will expire on July 10, 2019.
TARGET AUDIENCE
This activity has been designed to meet the educational needs of primary care clinicians, nurse practitioners (NPs), physician assistants (PAs) and other health care professionals involved in the care of patients with diabetes.
This activity has been designed to meet the educational needs of primary care clinicians, nurse practitioners (NPs), physician assistants (PAs) and other health care professionals involved in the care of patients with diabetes.
SUPPORTER STATEMENT
This activity was supported by an educational grant from Sanofi US.
ACCREDITATION STATEMENT
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the providership of Horizon CME. Horizon CME is accredited by the ACCME to provide continuing medical education for physicians.
CREDIT DESIGNATION
Horizon CME designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
HOW TO CLAIM CREDIT
- Read the learning objectives and faculty disclosures.
- Participate in the activity.
- Complete the post-test and activity evaluation.
- Physicians who successfully complete the post-test and evaluation will receive CME credit. You must score with an 75% or higher on the post-test to receive credit for this activity.
- All other participants who successfully complete the post-test and evaluation will receive a certificate of participation.
Statement of credit will be available to print from your user history page.
LEARNER ASSURANCE STATEMENT
Horizon CME requires instructors, planners, managers and other individuals who are in a position to influence the content of this activity to disclose any real or apparent conflict of interest (COI) which may arise as a result of prospective faculty members' relevant relationships with drug or device manufacturer(s). Horizon CME is committed to resolving all conflicts of interest and retaining only those speakers with financial interest conflicts that can be reconciled with the goals and educational integrity of the CME activity.
| Name of Faculty | Reported Financial Relationship |
|---|---|
| Carol Wysham, MD | Dr. Wysham has served on Speakers Bureaus for Astra Zeneca, Boehringer Ingelheim, Eli Lilly and Company, Janssen, Insulet, Novo Nordisk and Sanofi. She has served on Advisory Boards for Abbott, Astra Zeneca, Janssen, Novo Nordisk and Sanofi. She has provided services for non-CME promotional purposes for Sanofi and Novo Nordisk. |
| Davida F. Kruger, MSN, APN-BC, BC-ADM | Ms. Kruger has served on Advisory Boards for Abbott, Eli Lilly and Company, Janssen, Novo Nordisk, sanofi, Dexcom, Intarcia and Merck. She has served on Speakers Bureaus for Abbott, Astra Zeneca, Boehringer Ingelhemi/Lilly, Eli Lilly and Company, Janssen, Novo Nordisk, Dexcom, Insulet and Valeritas. Her institution has received grants/research support from Abbott, Astra Zeneca, Eli Lilly and Company, Novo Nordisk, Dexcom, and Lexicon. Ms. Kruger is a stockholder in Dexcom. |
| Felice Caldarella, MD, FACE, FACP, CDE | Dr. Calderella discloses no relevant financial relationships with ACCME-defined commercial interests during the past 12 months. |
HORIZON PLANNER DISCLOSURES
Horizon CME planners, non-faculty contributors and others involved in the planning, development, and editing/review of the content disclosed no relevant financial relationships with any ACCME-defined commercial interests during the past 12 months.
DISCLOSURE OF UNLABELED USE
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.
The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Disclaimer
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient's conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer's product information, and comparison with recommendations of other authorities.
DISCLOSURE OF UNLABELED USE
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.
The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Disclaimer
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient's conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer's product information, and comparison with recommendations of other authorities.
COURSE VIEWING REQUIREMENTS
| Supported Browsers: Internet Explorer 8.0+ for Windows 2000, 2003, Vista, XP, Windows 7, Windows 8 Google Chrome 28.0+ for Windows, Mac OS, or Linux Mozilla Firefox 23.0+ for Windows, Mac OS, or Linux Safari 6+ for Mac OSX 10.7 and above For video playback, install the latest version of Flash or Quicktime. | Supported Phones & Tablets: Android 4.0.3 and above iPhone/iPad with iOS 6.1 or above |
